Abstract
Quantifying the effect of non-pharmaceutical interventions (NPIs) is essential for formulating lessons from the COVID-19 pandemic. To enable a more reliable and rigorous evaluation of NPIs based on time series data, we reanalyse the data for the original official evaluation of NPIs in Germany using an ensemble of 9 competitive statistical methods for estimating the effects of NPIs and other determinants of disease spread on the effective reproduction number ℛ(t) and the associated error bars. A proper error analysis for time series data leads to significantly wider confidence intervals than the official evaluation. In addition to vaccination and seasonality, only few NPIs – such as restrictions in public spaces – can be confidently associated with variations in ℛ(t), but even then effect sizes have large uncertainties. Furthermore, due to multicollinearity in NPI activation patterns, it is difficult to distinguish potential effects of NPIs in public spaces from other interventions that came into force early, such as physical distancing. In future, NPIs should be more carefully designed and accompanied by plans for data collections to allow for a timely evaluation of benefits and harms as a basis for an effective and proportionate response.
Competing Interest Statement
B.M., I.P., M.L., and R.B. are signatories of a call for a non-partisan pandemic review in Germany (https://pandemieaufarbeitung.net). B.M. has been engaged in discussion and consultation of pandemic policy and science policy with members of several German parties (CDU, CSU, FDP, SPD, BSW, Greens), but is not receiving remuneration. S.C., M.G.M.G., D.H. and J.P.A.I. have no competing interests to declare.
Funding Statement
There is no funding to report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.